Alnylam CEO predicts more NME approvals in 2013

12/26/2012 | Xconomy

Drugmakers have improved at developing innovative medicines, and the FDA has struck a better balance in assessing risks and benefits, writes Alnylam Pharmaceuticals CEO John Maraganore. The result will be increasing approvals of new molecular entities, he predicts.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI